, Volume 71, Issue 16, pp 2193–2212 | Cite as


A Review of its Use in the Treatment of Postmenopausal Osteoporosis
Adis Drug Evaluation


Bazedoxifene (Conbriza®, Viviant®) is the first third-generation selective estrogen receptor modulator (SERM) and it is approved for the treatment of postmenopausal osteoporosis in the EU and Japan. Bazedoxifene contains an indole-based core binding domain that binds with high affinity to estrogen receptors and exhibits favourable effects on bone and lipid profiles, with no clinically relevant endometrial or breast stimulation. Oral bazedoxifene once daily reduced the incidence of new vertebral fractures in patients with postmenopausal osteoporosis in a large, well designed trial of 3 years’ duration; both bazedoxifene and raloxifene were significantly more effective than placebo. Neither bazedoxifene nor raloxifene reduced the incidence of nonvertebral fractures in the overall study population; however, bazedoxifene, but not raloxifene, reduced the rate of nonvertebral fractures in high-risk patients. Moreover, data from patients who continued to receive the drug during a 2-year extension phase of this trial indicate that bazedoxifene continues to provide protection against new vertebral fractures for up to 5 years. Bazedoxifene also increases bone mineral density and reduces the levels of bone turnover markers. Bazedoxifene was generally well tolerated and did not detrimentally affect the reproductive tract or breast tissue in clinical trials, thereby demonstrating a favourable risk-benefit profile. A pharmacoeconomic analysis conducted from an EU perspective predicted bazedoxifene to be cost effective in some EU countries.Therefore, bazedoxifene presents another useful option for the treatment of post-menopausal osteoporosis, especially in those at high risk for osteoporotic fracture.


  1. 1.
    Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause 2010; 17(1): 25–54CrossRefGoogle Scholar
  2. 2.
    World Health Organisation. Prevention and management of osteoporosis: report of a WHO scientific group. WHO technical report series [online]. Available from URL: http://whqlibdoc.who.int/trs/who_trs_921.pdf [Accessed 2011 Jul 18]
  3. 3.
    International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact [online]. Available from URL: http://www.iofbonehealth.org/facts-and-statistics.html#factsheet-category-14 [Accessed 2011 Jul 18]
  4. 4.
    Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res 2007 Mar; 22(3): 465–75PubMedCrossRefGoogle Scholar
  5. 5.
    Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. Technical report [online]. Available from URL: http://www.sheffield.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf [Accessed 2011 Jul 18]
  6. 6.
    Kanis JA, Burlet N, Cooper C, et al. European guidance for the diagnosis and management of osteoporosis in post-menopausal women. Osteoporos Int 2008 Apr; 19(4): 399–428PubMedCrossRefGoogle Scholar
  7. 7.
    Itabashi A, Yoh K, Chines AA, et al. Effects of bazedoxifene on bone mineral density, bone turnover, and safety in postmenopausal Japanese women with osteoporosis. J Bone Miner Res 2011; 26(3): 519–29PubMedCrossRefGoogle Scholar
  8. 8.
    Xu L, Tsai KS, Kim GS. Efficacy and safety of bazedoxifene in postmenopausal Asian women. Osteoporos Int 2011; 22(2): 559–65PubMedCrossRefGoogle Scholar
  9. 9.
    International Osteoporosis Foundation. Osteoporosis and you [online]. Available from URL: http://www.iofbonehealth.org/publications/osteoporosis-and-you.html [Accessed 2011 Jul 18]
  10. 10.
    Felsenberg D, Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin Ther 2005; 27(1): 1–11PubMedCrossRefGoogle Scholar
  11. 11.
    Reginster JY. Antifracture efficacy of currently available therapies for postmenopausal osteoporosis. Drugs 2010; 70(18): 65–78Google Scholar
  12. 12.
    MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008 Feb 5; 148(3): 197–213PubMedGoogle Scholar
  13. 13.
    National Osteoporosis Foundation. Clinicians guide to the prevention and treatment of osteoporosis [online]. Available from URL: http://www.nof.org/sites/default/files/pdfs/NOF_ClinicianGuide2009_v7.pdf [Accessed 2011 Jul 18]
  14. 14.
    Gennari L, Merlotti D, Valleggi F, et al. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs Aging 2007; 24(5): 361–79PubMedCrossRefGoogle Scholar
  15. 15.
    Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000 Aug; 60(2): 379–411PubMedCrossRefGoogle Scholar
  16. 16.
    European Medicines Agency. Conbriza 20 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000913/WC500033577.pdf [Accessed 2010 Jul 18]
  17. 17.
    Viviant tablets 20 mg [package insert]. Tokyo: Pfizer Japan Inc. 2010Google Scholar
  18. 18.
    US National Institutes of Health. ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2011 Jul 18]
  19. 19.
    Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005 Sep; 146(9): 3999–4008PubMedCrossRefGoogle Scholar
  20. 20.
    Komm BS, PVN, Minck DR. Effects of bazedoxifene acetate on bone loss: a 12-month study in ovariectomised rats [abstract no M404]. J Bone Miner Res 2007 Sep 1; 22 Suppl. 1: 206Google Scholar
  21. 21.
    Pfizer Japan Inc. Data on file. 2011Google Scholar
  22. 22.
    European Medicines Agency. Assessment report for conbriza [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000913/WC500033576.pdf [Accessed 2011 Jul 18]
  23. 23.
    Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008; 23(12): 1923–34PubMedCrossRefGoogle Scholar
  24. 24.
    Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008; 23(4): 525–35PubMedCrossRefGoogle Scholar
  25. 25.
    Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005; 105(6): 1397–404PubMedCrossRefGoogle Scholar
  26. 26.
    Taylor HS. Approaching the ideal selective estrogen receptor modulator for prevention and treatment of post-menopausal osteoporosis. Formulary 2010; 45(2): 52–61Google Scholar
  27. 27.
    Fujiwara S, Nakamura T, Orimo H, et al. Development and application of a Japanese model of the WHO fracture risk assessment tool (FRAX). Osteoporos Int 2008 Apr; 19(4): 429–35PubMedCrossRefGoogle Scholar
  28. 28.
    Orimo H, Hayashi Y, Fukunaga M, et al. Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 2001; 19(6): 331–7PubMedCrossRefGoogle Scholar
  29. 29.
    Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009; 16(6): 1102–8PubMedCrossRefGoogle Scholar
  30. 30.
    Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009; 16(6): 1109–15PubMedCrossRefGoogle Scholar
  31. 31.
    de Villiers TJ, Chines AA, Palacios S, et al. Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int 2011; 22: 567–76PubMedCrossRefGoogle Scholar
  32. 32.
    Christiansen C, Chesnut CH, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskeletal Disorders 2010; 11 (130)Google Scholar
  33. 33.
    Harvey JA, Holm MK, Ranganath R, et al. The effects of bazedoxifene on mammographic breast density in post-menopausal women with osteoporosis. Menopause 2009; 16(6): 1193–6PubMedCrossRefGoogle Scholar
  34. 34.
    Chandrasekaran A, McKeand WE, Sullivan P, et al. Metabolic disposition of [14C] bazedoxifene in healthy, post-menopausal women. Drug Metab Dispos 2009 Jun; 37(6): 1219–25PubMedCrossRefGoogle Scholar
  35. 35.
    Shen L, Ahmad S, Park S, et al. In vitro metabolism, permeability, and efflux of bazedoxifene in humans. Drug Metab Dispos 2010 Sep; 38(9): 1471–9PubMedCrossRefGoogle Scholar
  36. 36.
    European Medicines Agency. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis: Committee for Medicinal Products For Human Use (CHMP) [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003405.pdf [Accessed 2011 Jul 18]
  37. 37.
    Chines AA, Zanchetta JR, Genant HK, et al. Sustained efficacy of bazedoxifene in preventing fractures in post-menopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study [abstract no. OC17]. Osteoporosis Int 2010 May 5; 21 Suppl. 1: S7–24CrossRefGoogle Scholar
  38. 38.
    Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009 Jun; 44(6): 1049–54PubMedCrossRefGoogle Scholar
  39. 39.
    World Health Organisation Collaborating Centre for Metabolic Bone Diseases. FRAX® WHO fracture risk assessment tool [online]. Available from URL: http://www.sheffield.ac.uk/FRAX/ [Accessed 2011 Jul 18]
  40. 40.
    Borgstrom F, Strom O, Kleman M, et al. Cost-effectiveness of bazedoxifene incorporating the FRAX® algorithm in a European perspective. Osteoporos Int 2011; 22(3): 955–65PubMedCrossRefGoogle Scholar
  41. 41.
    Strom O, Borgstrom F, Kleman M, et al. FRAX and its applications in health economics: cost-effectiveness and intervention thresholds using bazedoxifene in a Swedish setting as an example. Bone 2010 Aug; 47(2): 430–7PubMedCrossRefGoogle Scholar
  42. 42.
    Miller PD, Derman RJ. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporosis Int 2010; 21(11): 1793–802CrossRefGoogle Scholar
  43. 43.
    Pazianas M, Cooper C, Ebitino FH. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 2010; 6: 325–43PubMedGoogle Scholar
  44. 44.
    Lewiecki EM. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Drugs 2011; 71(6): 791–814PubMedCrossRefGoogle Scholar
  45. 45.
    Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging 2011; 28(1): 63–82PubMedCrossRefGoogle Scholar
  46. 46.
    Deeks ED, Dhillon S. Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis. Drugs 2010 Apr 16; 70(6): 733–59PubMedCrossRefGoogle Scholar
  47. 47.
    Watts NB. Postmenopausal osteoporosis: what’s new and what’s next. Sex Reprod Menopause 2010; 8 (2)Google Scholar
  48. 48.
    Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288(3): 321–33PubMedCrossRefGoogle Scholar
  49. 49.
    Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [published erratum appears in JAMA 1999 Dec 8; 282 (22): 2124]. JAMA 1999 Jun 16; 281(23): 2189–97Google Scholar
  50. 50.
    Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003 Oct; 33(4): 522–32PubMedCrossRefGoogle Scholar
  51. 51.
    Rice VM. Strategies and issues for managing menopause-related symptoms in diverse populations: ethnic and racial diversity. Am J Med 2005; 118 Suppl. 12B: 142–7PubMedCrossRefGoogle Scholar
  52. 52.
    Shea JL. Chinese women’s symptoms: relation to menopause, age and related attitudes. Climacteric 2006 Feb; 9(1): 30–9PubMedCrossRefGoogle Scholar
  53. 53.
    Melby MK, Lock M, Kaufert P. Culture and symptom reporting at menopause. Hum Reprod Update 2005; 11(5): 495–512PubMedCrossRefGoogle Scholar
  54. 54.
    Melby MK. Vasomotor symptom prevalence and language of menopause in Japan. Menopause 2005; 12(3): 250–7PubMedCrossRefGoogle Scholar
  55. 55.
    Pinkerton JV, Goldstein SR. Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. Menopause 2010; 17(3): 642–53PubMedGoogle Scholar
  56. 56.
    European Medicines Agency. Evista 60 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000184/WC500031011.pdf [Accessed 2011 Jul 11]
  57. 57.
    European Medicines Agency. Fablyn 500 microgram film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000977/WC500020092.pdf [Accessed 2011 Jul 11]
  58. 58.
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [published erratum appears in JAMA 1999 Dec 8; 282 (22): 2124]. JAMA 1999 Aug 18; 282(7): 637–45Google Scholar
  59. 59.
    Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11(1): 83–91Google Scholar
  60. 60.
    Wyeth Pharmaceuticals. Study evaluating bazedoxifene acetate in osteoporosis in postmenopausal women [ClinicalTrials.gov identifier NCT00205777]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00205777?term=bazedoxifene&rank=6 [Accessed 2011 Jul 18]
  61. 61.
    Kanis JA, Oden A, Johnell O, et al. Uncertain future of trials in osteoporosis. Osteoporos Int 2002; 13(6): 443–9PubMedCrossRefGoogle Scholar
  62. 62.
    Schmidt C. Third-generation SERMs may face uphill battle. J Natl Cancer Inst 2010 Nov 17; 102(22): 1690–2PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore, AucklandNew Zealand

Personalised recommendations